Key result
Current evidence does not support routine anticoagulation therapy for new-onset atrial fibrillation during sepsis, as it increases bleeding risk without a clear benefit in reducing thromboembolic events.
Why the study?
Does anticoagulation therapy reduce thromboembolic events without excessive bleeding in critically ill ICU patients with sepsis and new-onset atrial fibrillation?
Does anticoagulation therapy reduce thromboembolic events without excessive bleeding in critically ill ICU patients with sepsis and new-onset atrial fibrillation?
Routine anticoagulation for new-onset atrial fibrillation in patients with sepsis is not currently recommended due to an unfavorable risk-benefit profile driven by increased bleeding.
Atrial fibrillation (AF) is the most common arrhythmia observed in clinical practice. New-onset AF is reported to occur in 2% to 44% of critically ill ICU patients, with the highest rates observed in patients with septic shock.(,) A recent prospective study of 1,423 intensive care unit (ICU) patients revealed that 15.6% developed AF, with 13.3% […]
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2025) conducted an editorial in Sepsis with new-onset atrial fibrillation. Anticoagulation therapy vs. No routine anticoagulation was evaluated. Current evidence does not support routine anticoagulation therapy for new-onset atrial fibrillation during sepsis, as it increases bleeding risk without a clear benefit in reducing thromboembolic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: